4//SEC Filing
NPS PHARMACEUTICALS INC 4
Accession 0001104659-15-007835
CIK 0000890465operating
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 4:37 PM ET
Size
17.0 KB
Accession
0001104659-15-007835
Insider Transaction Report
Form 4
Rogus Joseph J
VP, Technical Operations
Transactions
- Exercise/Conversion
Employee Stock Options (right to buy)
2015-02-05−4,313→ 69,738 totalExercise: $3.34Exp: 2020-02-19→ Common Stock (4,313 underlying) - Exercise/Conversion
Common Stock
2015-02-05$8.25/sh+16,875$139,219→ 37,026 total - Exercise/Conversion
Common Stock
2015-02-05$8.23/sh+11,434$94,102→ 48,460 total - Exercise/Conversion
Employee Stock Options (right to buy)
2015-02-05−16,875→ 2,813 totalExercise: $8.25Exp: 2021-02-17→ Common Stock (16,875 underlying) - Exercise/Conversion
Common Stock
2015-02-05$3.34/sh+4,313$14,405→ 52,773 total - Sale
Common Stock
2015-02-05$45.90/sh−32,622$1,497,245→ 20,151 total - Exercise/Conversion
Employee Stock Options (right to buy)
2015-02-05−11,434→ 14,702 totalExercise: $8.23Exp: 2023-02-13→ Common Stock (11,434 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.89 to $45.93, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- [F2]On February 17, 2011, the reporting person received a grant of 45,000 stock options under the Issuer's 1998 Stock Option Plan. The options became exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter.
- [F3]On February 13, 2013, the reporting person received a grant of 26,136 stock options under the Issuer's 2005 Omnibus Incentive Plan. The options became exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter.
- [F4]On February 19, 2010, the reporting person was granted options to purchase shares of common stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of the date of this filing, the performance criteria and the time-based criteria for 112,125 of these options has been satisfied. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.
Documents
Issuer
NPS PHARMACEUTICALS INC
CIK 0000890465
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000890465
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 4:37 PM ET
- Size
- 17.0 KB